WHAT IS CLAIMED IS:

1. A double-stranded ribonucleic acid comprising:

a combination of a sense strand and an antisense strand,

wherein the combination of the sense strand and the antisense strand are selected from the group consisting of combinations:

SEQ ID NO: 159 and SEQ ID NO: 160; SEQ ID NO: 141 and SEQ ID NO: 142; SEQ ID NO: 143 and SEQ ID NO: 144; SEQ ID NO: 145 and SEQ ID NO: 146; SEQ ID NO: 147 and SEQ ID NO: 148; and SEQ ID NO: 153 and SEQ ID NO: 154.

2. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 159; and an antisense strand of SEQ ID NO: 160.

~~3. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 141; and an antisense strand of SEQ ID NO: 142.~~

~~4. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 143; and an antisense strand of SEQ ID NO: 144.~~

~~5~~3. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 145; and an antisense strand of SEQ ID NO: 146.

~~6. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 147; and an antisense strand of SEQ ID NO: 148.~~

~~7~~4. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 153; and an antisense strand of SEQ ID NO: 154.

~~8. A pharmaceutical composition comprising:~~

~~the double-stranded ribonucleic acid according to any one of claims 1 to 7.~~

~~9. The pharmaceutical composition according to claim 8, for treating paroxysmal nocturnal hemoglobinuria.~~

~~10. The pharmaceutical composition according to claim 8, for treating atypical hemolytic uremic syndrome.~~

~~11~~5. A lipid complex encapsulating the double-stranded ribonucleic acid according to claim 1~~any one of claims 1 to 7~~.

~~12~~6. The lipid complex according to claim ~~11~~5, comprising:

a cationic lipid; and

at least one lipid selected from the group consisting of neutral lipid, polyethylene glycol-modified lipid, and sterol.

~~13~~7. The lipid complex according to claim ~~12~~6, wherein the cationic lipid is 2-{9-oxo-9-[(3-pentyloctyl)oxy]nonyl}dodecyl 1-methylpiperidine-4-carboxylate.

8. A lipid complex encapsulating the double-stranded ribonucleic acid according to claim 3.

9. The lipid complex according to claim 8, comprising:

a cationic lipid; and

at least one lipid selected from the group consisting of neutral lipid, polyethylene glycol-modified lipid, and sterol.

10. The lipid complex according to claim 9, wherein the cationic lipid is

2-{9-oxo-9-[(3-pentyloctyl)oxy]nonyl}dodecyl 1-methylpiperidine-4-carboxylate.

11. A pharmaceutical composition comprising:

the double-stranded ribonucleic acid according to claim 1 and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising:

the double-stranded ribonucleic acid according to claim 2 and a pharmaceutically acceptable carrier.

13. A pharmaceutical composition comprising:

the double-stranded ribonucleic acid according to claim 3 and a pharmaceutically acceptable carrier.

14. A pharmaceutical composition comprising:

the double-stranded ribonucleic acid according to claim 4 and a pharmaceutically acceptable carrier.

~~14~~15. A pharmaceutical composition comprising:

the lipid complex according to claim 5 and a pharmaceutically acceptable carrier~~any one of claims 11 to 13~~.

16. A pharmaceutical composition comprising:

the lipid complex according to claim 8 and a pharmaceutically acceptable carrier.

17. Use of the pharmaceutical composition according to claim 13 in the manufacture of a medicament for treating paroxysmal nocturnal

hemoglobinuria.

18. Use of the pharmaceutical composition according to claim 13 in the manufacture of a medicament for treating atypical hemolytic uremic syndrome.

19. Use of the pharmaceutical composition according to claim 16 in the manufacture of a medicament for treating paroxysmal nocturnal hemoglobinuria.

20. Use of the pharmaceutical composition according to claim 16 in the manufacture of a medicament for treating atypical hemolytic uremic syndrome.

~~15. The pharmaceutical composition according to claim 14, for treating paroxysmal nocturnal hemoglobinuria.~~

~~16. The pharmaceutical composition according to claim 14, for treating atypical hemolytic uremic syndrome.~~

~~17. The double-stranded ribonucleic acid according to any one of claims 1 to 7, for use in treating paroxysmal nocturnal hemoglobinuria.~~

~~18. The double-stranded ribonucleic acid according to any one of claims 1 to 7, for use in treating atypical hemolytic uremic syndrome.~~

~~19. The lipid complex according to any one of claims 11 to 13, for use in treating paroxysmal nocturnal hemoglobinuria.~~

~~20. The lipid complex according to any one of claims 11 to 13, for use in treating atypical hemolytic uremic syndrome.~~

~~21. Use of the double-stranded ribonucleic acid according to any one of claims 1 to 7, in the manufacture of a pharmaceutical composition for treating paroxysmal nocturnal hemoglobinuria.~~

~~22. Use of the double-stranded ribonucleic acid according to any one of claims 1 to 7, in the manufacture of a pharmaceutical composition for treating atypical hemolytic uremic syndrome.~~

~~23. Use of the lipid complex according to any one of claims 11 to 13, in the manufacture of a pharmaceutical composition for treating paroxysmal nocturnal hemoglobinuria.~~

~~24. Use of the lipid complex according to any one of claims 11 to 13, in the manufacture of a pharmaceutical composition for treating atypical hemolytic uremic syndrome.~~